
Oncolytics Biotech fell 67.6% from $1.05 to $0.34, behind the S&P 500's +11.2%. Its worst day was Oct 12 (−15.0%), and its low came Nov 16 at $0.34.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Oncolytics Biotech closed at its highest level of the year, 21.0% above where the year started.
+8.5% · S&P 500 +0.5%
Story events cover the past 12 months · Times ET
Oncolytics Biotech shares rose 27.0%, while the S&P 500 rose 0.1%.
+27.0%, the year's best day · S&P 500 +0.1%
EPS of $-0.09 missed the $-0.07 estimate on $0.00 revenue.
−4.2% · S&P 500 −0.3%
Oncolytics Biotech shares rose 14.8%, while the S&P 500 rose 0.6%.
+14.8% · S&P 500 +0.6%
EPS of $-0.06 beat the $-0.07 estimate on $0.00 revenue.
−2.6% · S&P 500 −1.2%
Oncolytics Biotech shares rose 16.1%, while the S&P 500 rose 0.8%.
+16.1% · S&P 500 +0.8%
EPS of $-0.08 missed the $-0.07 estimate on $0.00 revenue.
+0.5% · S&P 500 +0.3%
Oncolytics Biotech shares fell 15.0%, while the S&P 500 fell 0.1%.
−15.0%, the year's worst day · S&P 500 −0.1%
EPS of $-0.08 missed the $-0.07 estimate on $0.00 revenue.
−8.1% · S&P 500 −1.9%
Where it ended: a close of $0.34 on Nov 16, 2026.
Nothing in the past 12 months.
All ONCY dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ONCY and SPY from Benzinga historical bars. Not investment advice.